alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I never expected IMGN would drop so much so quickly on zero moves so I bought more this morning at $14.40.
Doc328,
Thanks for your knowledgable first-hand comments. They reinforce my view that the Q2 numbers aren't that important. What matters is how Daxxify will be taken up with time, and how approval in the CD indication affects uptake in that market.
Given the numbers you cited, does that mean your practice overall isn't very dependent on toxins for patient population and revenues?
Dewophile, I agree with your comments. It does seem insensitive if not callous to just dismiss the possibility of twice the duration have value to a patient. A caring physician might investigate a bit and tell patients about a potential/likely longer lasting treatment and ask if they were interested.
August is an important month for RVNC. Q2 earning will be next Tuesday after close and the PDUFA decision for Daxxify in CD is in less than 3 weeks.
https://finance.yahoo.com/news/revance-release-second-quarter-2023-120000360.html
EXEL shows impressive revenue growth and finally shows some stock price appreciation.
https://www.fool.com/earnings/call-transcripts/2023/08/02/exelixis-exel-q2-2023-earnings-call-transcript/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Lots of good news and things to look forwards to in IMGN's earnings report.
https://finance.yahoo.com/news/q2-2023-immunogen-inc-earnings-061621019.html
The NIH is running trials to assess therapies that might help combat long Covid. I guess Jake should tell the NIH they don't know what they are doing.
The NIH is running trials to assess therapies that might help combat long Covid. I guess Jake should tell the NIH they don't know what they are doing.
Blowout earnings report today so things are looking up for IMGN investors no matter what the profit-takers are doing.
The market reaction often makes me laugh, but that is what makes market opportunities. IMGN sales of Elahere blew away expectations as sales estimates for Q2 were in the low $44 million but came in at $77 million. The Chief Medical Officer announced she was leaving so it looks like that is what the market focused on. I remain bullish.
https://investor.immunogen.com/news-releases/news-release-details/immunogen-reports-recent-progress-and-second-quarter-2023
ABBV-903 is a different anti-Covid drug that has only been tested in a 24 patient phase I safety trial. It has been listed as a protease inhibitor. If ABBV is showing interest in protease inhibitors, then EDP-235 remains a potential partner.
The previous links you provided were all about an antibody ABBV-47D11, which is infused for treatment of Covid. In that very small phase I trial, most patients were already hospitalized and looking at the data, there was not a dose dependence to anti-viral effects. In any event, it is a distinct patient population than either Paxlovid or EDP-235. In my view, ABBV is still a potential partner for ENTA .
As far as ABBV-744, it is different drug than first announced in 2020 as a possible protease inhibitor. That was when companies were throwing everything against the wall to see what would stick to combat the pandemic. As far as I can see, ABBV-744 appears dead in the water as an anti-Covid drug as I can find nothing since that initial report you cited ~3 years ago.
MRSN craters some 80% today on failure to meet primary endpoint in platinum resistant ovarian cancer, announces strategic reorganization. Ouch! IMGN shareholders know a bit how that felt a few years ago when the Forward 1 trial meet its primary end point. The difference was that after the fact data analysis showed that high alpha foliate receptor expressing patients showed efficacy with Elahare. That was borne out in the SORAYA & MIRASOL trials. However, avenue doesn't seem like a possibility for MRSN as the NaPi2b positive patients, the target for their ADC, looked similar to the general population in their trial.
https://finance.yahoo.com/news/mersana-therapeutics-announces-topline-data-110600082.html